{"filing":{"accession_number":"0001193125-26-343477","cik":"0001754068","ticker":"KLRS","company_name":"Kalaris Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-11","report_date":"2026-08-11","primary_document":"d114296d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312526343477/d114296d8k.htm"},"events":[{"id":26905,"run_id":24472,"accession_number":"0001193125-26-343477","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a clear earnings release disclosing Kalaris Therapeutics' financial results for the quarter ended June 30, 2026. The Item 2.02 disclosure explicitly states the company \"issued a press release announcing the Company's financial results for the quarter ended June 30, 2026,\" with the press release furnished as Exhibit 99.1. The exhibit contains condensed consolidated statements of operations and balance sheets, along with detailed discussion of R\u0026D expenses ($9.0M), G\u0026A expenses ($3.4M), net loss ($11.5M), and cash position ($93.5M). This is a material disclosure affecting investor assessment of the registrant's financial condition and operational performance.","company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","filing_date":"2026-08-11","form":"8-K","submitted_at":null,"items":[{"id":28200,"accession_number":"0001193125-26-343477","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Kalaris Therapeutics' financial results for the quarter ended June 30, 2026. The Item 2.02 disclosure explicitly states the company \"issued a press release announcing the Company's financial results for the quarter ended June 30, 2026,\" with the press release furnished as Exhibit 99.1. The exhibit contains condensed consolidated statements of operations and balance sheets, along with detailed discussion of R\u0026D expenses ($9.0M), G\u0026A expenses ($3.4M), net loss ($11.5M), and cash position ($93.5M). This is a material disclosure affecting investor assessment of the registrant's financial condition and operational performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T12:06:50.263758+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28200,"accession_number":"0001193125-26-343477","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Kalaris Therapeutics' financial results for the quarter ended June 30, 2026. The Item 2.02 disclosure explicitly states the company \"issued a press release announcing the Company's financial results for the quarter ended June 30, 2026,\" with the press release furnished as Exhibit 99.1. The exhibit contains condensed consolidated statements of operations and balance sheets, along with detailed discussion of R\u0026D expenses ($9.0M), G\u0026A expenses ($3.4M), net loss ($11.5M), and cash position ($93.5M). This is a material disclosure affecting investor assessment of the registrant's financial condition and operational performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T12:06:50.263758+00:00","company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","filing_date":"2026-08-11"}]}